Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150mg ibandronate with once-weekly oral administration of 70mg alendronate in postmenopausal osteoporosis - non-inferiority trial.

Next Previous
X
Search
Trial Profile

Randomized, double-blind, double-dummy, parallel group, multicenter study to compare the efficacy and safety of once-monthly oral administration of 150mg ibandronate with once-weekly oral administration of 70mg alendronate in postmenopausal osteoporosis - non-inferiority trial.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 31 Aug 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ibandronic acid (Primary) ; Alendronic acid
  • Indications Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms MOTION

    • Most Recent Events

    • 01 Jan 2008 Results have been published.
    • 19 Sep 2007 Primary endpoint reported by GlaxoSmithKline.
    • 19 Sep 2007 Tolerability data reported at ASBMR 2007.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top